Psoas Muscle Density Predicts Occurrences of Hepatic Encephalopathy in Patients Receiving Transjugular Intrahepatic Portosystemic Shunts within 1 year

Cai, Weimin; Lin, Han-Yu; Qi, Ruyi; Lin, Xiuqing; Zhao, Yuan; Chen, Weizhen; Huang, Zhiming

doi:10.1007/s00270-021-02961-8

Cited by 12 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The predictive accuracy of the inverse stepwise LR model was superior to established scores such as MELD, ALBI, and Child-Pugh score. The integration of AI with CT imaging techniques may help to assess the risk of HE morbidity [115] .…”

Section: Advances In the Application Of Ai To The Evaluation Of Hementioning

confidence: 99%

Hepatic encephalopathy post-TIPS: Current status and prospects in predictive assessment

Xu,

Yang,

Tan

et al. 2024

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

Section: Advances In the Application Of Ai To The Evaluation Of Hementioning

confidence: 99%

Hepatic encephalopathy post-TIPS: Current status and prospects in predictive assessment

Xu,

Yang,

Tan

et al. 2024

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

“…Moreover, myosteatosis has been associated with higher mortality in LC patients [ 22 , 107 , 118 ] and with the risk of developing HE in LC patients [ 20 , 119 ], but not with the length of hospital stay in patients with decompensated cirrhosis [ 120 ].…”

Section: Sarcopeniamentioning

confidence: 99%

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease

Musio

Perazza

Leoni

et al. 2023

IJMS

View full text Add to dashboard Cite

Chronic liver disease (CLD), including non-alcoholic fatty liver disease (NAFLD) and its advanced form, non-alcoholic steatohepatitis (NASH), affects a significant portion of the population worldwide. NAFLD is characterised by fat accumulation in the liver, while NASH is associated with inflammation and liver damage. Osteosarcopenia, which combines muscle and bone mass loss, is an emerging clinical problem in chronic liver disease that is often underappreciated. The reductions in muscle and bone mass share several common pathophysiological pathways; insulin resistance and chronic systemic inflammation are the most crucial predisposing factors and are related to the presence and gravity of NAFLD and to the worsening of the outcome of liver disease. This article explores the relationship between osteosarcopenia and NAFLD/MAFLD, focusing on the diagnosis, prevention and treatment of this condition in patients with CLD.

show abstract

“…Several studies confirm the relationship between poor body composition status and post-TIPS HE. Two studies found a thin or low-density psoas muscle CT scan to be associated with high post-TIPS HE incidence [ 33 , 73 ]. Other studies used skeletal muscle index (ratio of the muscle in arms and legs to height) as a measure of sarcopenia and found that 50 out of 56 patients with sarcopenia and none of the 6 patients without sarcopenia developed post-TIPS HE and that patients with improvement in skeletal muscle index reversing from sarcopenic to non-sarcopenic had a lower risk of developing post-TIPS OHE 6 months after TIPS [ 32 , 74 , 75 ].…”

Section: Risk Factorsmentioning

confidence: 99%

Post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) Hepatic Encephalopathy—A Review of the Past Decade’s Literature Focusing on Incidence, Risk Factors, and Prophylaxis

Friis,

Thomsen,

Laleman

et al. 2023

JCM

View full text Add to dashboard Cite

Transjugular intrahepatic portosystemic shunt (TIPS) is an established treatment for portal hypertension and its’ complications in liver cirrhosis, yet the development of hepatic encephalopathy (HE) remains a significant concern. This review covers the reported incidence, risk factors, and management strategies for post-TIPS HE over the past decade. Incidence varies widely (7–61%), with factors like age, liver function, hyponatremia, and spontaneous portosystemic shunts influencing risk. Procedural aspects, including TIPS timing, indication, and stent characteristics, also contribute. Pharmacological prophylaxis with lactulose and rifaximin shows promise, but current evidence is inconclusive. Procedural preventive measures, such as shunt embolization and monitoring portal pressure gradients, are explored. Treatment involves pharmacological options like lactulose and rifaximin, and procedural interventions like stent diameter reduction. Ongoing studies on novel predictive markers and emerging treatments, such as faecal microbiota transplant, reflect the evolving landscape in post-TIPS HE management. This concise review provides clinicians with insights into the multifaceted nature of post-TIPS HE, aiding in improved risk assessment, prophylaxis, and management for patients undergoing TIPS procedures.

show abstract

Psoas Muscle Density Predicts Occurrences of Hepatic Encephalopathy in Patients Receiving Transjugular Intrahepatic Portosystemic Shunts within 1 year

Cited by 12 publications

References 44 publications

Hepatic encephalopathy post-TIPS: Current status and prospects in predictive assessment

Hepatic encephalopathy post-TIPS: Current status and prospects in predictive assessment

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease

Post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) Hepatic Encephalopathy—A Review of the Past Decade’s Literature Focusing on Incidence, Risk Factors, and Prophylaxis

Contact Info

Product

Resources

About